Stock TNYA TENAYA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.31 USD +2.13% Intraday chart for Tenaya Therapeutics, Inc. -0.23% +33.02%
Mar. 20 Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating MT
Mar. 19 North American Morning Briefing : Stock Futures -2- DJ

Business Summary

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.

Number of employees: 140

Managers

Managers TitleAgeSince
Faraz Ali CEO
 Chief Executive Officer 51 18-05-31
Leone Patterson DFI
 Director of Finance/CFO 61 21-05-31
Kee-Hong Kim CTO
 Chief Tech/Sci/R&D Officer - 18-09-30
Whittemore Tingley CTO
 Chief Tech/Sci/R&D Officer 56 18-11-30
Matthew Jay Pollman CTO
 Chief Tech/Sci/R&D Officer - -
Timothy Hoey CTO
 Chief Tech/Sci/R&D Officer 65 17-07-31
Michelle Corral IRC
 Investor Relations Contact - -
Sunita Sethi LAW
 General Counsel - -
Jennifer Drimmer LAW
 General Counsel - 22-01-09
Joanna Auch HRO
 Human Resources Officer - 21-12-21

Members of the board

Members of the board TitleAgeSince
Robert Williams BRD
 Director/Board Member 75 16-09-30
David Goeddel CHM
 Chairman 72 16-07-31
Jeffrey Walsh BRD
 Director/Board Member 58 20-02-29
Jin-Long Chen BRD
 Director/Board Member 61 16-09-30
Deepak Srivastava FOU
 Founder 57 16-09-30
Faraz Ali CEO
 Chief Executive Officer 51 18-05-31
Karah Parschauer BRD
 Director/Board Member 46 21-12-21
June Lee BRD
 Director/Board Member 58 21-11-18
Catherine Stehman-Breen BRD
 Director/Board Member 61 20-05-31
Amy Burroughs BRD
 Director/Board Member 53 22-12-06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 78,517,534 76,851,437 ( 97.88 %) 0 97.88 %

Shareholders

NameEquities%Valuation
The Column Group LLC
17.32 %
13,599,275 17.32 % 71 M $
Casdin Capital LLC
8.127 %
6,381,377 8.127 % 33 M $
RA Capital Management LP
7.014 %
5,507,347 7.014 % 29 M $
T. Rowe Price International Ltd.
5.788 %
4,544,543 5.788 % 24 M $
BlackRock Advisors LLC
4.632 %
3,636,940 4.632 % 19 M $
Fidelity Management & Research Co. LLC
3.381 %
2,654,751 3.381 % 14 M $
Vanguard Fiduciary Trust Co.
3.132 %
2,459,444 3.132 % 13 M $
Citadel Advisors LLC (13f Subfiler)
2.549 %
2,001,205 2.549 % 10 M $
Euclidean Capital LLC
1.294 %
1,015,705 1.294 % 5 M $
Geode Capital Management LLC
1.183 %
928,763 1.183 % 5 M $

Company contact information

Tenaya Therapeutics, Inc.

171 Oyster Point Boulevard 5th floor

94080, South San Francisco

+

http://www.tenayatherapeutics.com
address Tenaya Therapeutics, Inc.(TNYA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.31 USD
Average target price
19.43 USD
Spread / Average Target
+350.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TENAYA THERAPEUTICS, INC. Stock Tenaya Therapeutics, Inc.
+33.02% 338M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.37% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TNYA Stock
  4. Company Tenaya Therapeutics, Inc.